Shanghai Bowei

Shanghai Bowei Biopharmaceutical is a Chinese biotechnology company specializing in the research, development, and industrialization of recombinant protein vaccines. The company is primarily recognized for its advanced pipeline of Human Papillomavirus (HPV) vaccines, including quadrivalent and nonavalent candidates currently in Phase 3 clinical trials. Shanghai Bowei utilizes a proprietary Hansenula polymorpha yeast expression platform to produce high-quality virus-like particles (VLPs). As a key subsidiary of Walvax Biotechnology, the company benefits from significant financial backing and integrated manufacturing capabilities. Its mission is to provide affordable and effective vaccine solutions to address major public health challenges in China and globally. Beyond HPV, the company is exploring other viral targets and therapeutic vaccine technologies.